JP2020535832A - マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 - Google Patents

マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 Download PDF

Info

Publication number
JP2020535832A
JP2020535832A JP2020519092A JP2020519092A JP2020535832A JP 2020535832 A JP2020535832 A JP 2020535832A JP 2020519092 A JP2020519092 A JP 2020519092A JP 2020519092 A JP2020519092 A JP 2020519092A JP 2020535832 A JP2020535832 A JP 2020535832A
Authority
JP
Japan
Prior art keywords
cells
tcr
mtcr
antibody
amplification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020519092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535832A5 (enExample
Inventor
シー． デニガー、ドリュー
シー． デニガー、ドリュー
エー． フェルドマン、スティーヴン
エー． フェルドマン、スティーヴン
エー． ローゼンバーグ、スティーヴン
エー． ローゼンバーグ、スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2020535832A publication Critical patent/JP2020535832A/ja
Publication of JP2020535832A5 publication Critical patent/JP2020535832A5/ja
Priority to JP2023220106A priority Critical patent/JP7747724B2/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020519092A 2017-10-05 2018-09-24 マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 Pending JP2020535832A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023220106A JP7747724B2 (ja) 2017-10-05 2023-12-26 マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568339P 2017-10-05 2017-10-05
US62/568,339 2017-10-05
PCT/US2018/052432 WO2019070435A1 (en) 2017-10-05 2018-09-24 METHODS FOR SELECTIVE EXPANSION OF CELLS EXPRESSING A TCR WITH A CONSTANT MURINE REGION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023220106A Division JP7747724B2 (ja) 2017-10-05 2023-12-26 マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法

Publications (2)

Publication Number Publication Date
JP2020535832A true JP2020535832A (ja) 2020-12-10
JP2020535832A5 JP2020535832A5 (enExample) 2021-11-04

Family

ID=63841049

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020519092A Pending JP2020535832A (ja) 2017-10-05 2018-09-24 マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
JP2023220106A Active JP7747724B2 (ja) 2017-10-05 2023-12-26 マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023220106A Active JP7747724B2 (ja) 2017-10-05 2023-12-26 マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法

Country Status (13)

Country Link
US (1) US12227554B2 (enExample)
EP (2) EP3692140B1 (enExample)
JP (2) JP2020535832A (enExample)
KR (1) KR102757789B1 (enExample)
CN (1) CN111417720B (enExample)
AU (1) AU2018345400B2 (enExample)
CA (1) CA3077595A1 (enExample)
ES (1) ES2960313T3 (enExample)
FI (1) FI3692140T3 (enExample)
IL (1) IL273698B2 (enExample)
MA (1) MA50748A (enExample)
SG (1) SG11202003112QA (enExample)
WO (1) WO2019070435A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554674A (ja) * 2020-12-22 2023-12-28 ネオジン セラピューティクス ビー．ブイ． 遺伝子改変細胞追跡用ペプチドマーカー

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240175047A1 (en) 2021-02-25 2024-05-30 Alaunos Therapeutics, Inc. Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
US20250145950A1 (en) * 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11512284A (ja) * 1995-09-05 1999-10-26 ザ ジェネラル ホスピタル コーポレイション 単クローン性リンパ球及び利用方法
JP2003276960A (ja) * 2002-03-26 2003-10-02 Mitsubishi Electric Corp エレベーター制御システム
JP2008253267A (ja) * 1991-12-13 2008-10-23 Xoma Technology Ltd 改変抗体可変領域の調製のための物質ならびにその治療的用途
WO2016053339A1 (en) * 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
JP2016527230A (ja) * 2013-07-15 2016-09-08 アメリカ合衆国 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体
JP2017524372A (ja) * 2014-05-29 2017-08-31 アメリカ合衆国 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19905048A1 (de) 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Verwendung depletorisch oder mitogen wirkender Antikörper in der Immuntherapie
JP2003274960A (ja) * 2000-02-03 2003-09-30 Japan Science & Technology Corp 可溶性ｔ細胞受容体タンパク質およびその作成方法
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
US8772451B2 (en) * 2003-11-10 2014-07-08 Altor Bioscience Corporation Soluble TCR molecules and methods of use
WO2007131092A2 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
WO2008089053A2 (en) 2007-01-12 2008-07-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
ES2835200T3 (es) 2012-05-22 2021-06-22 Us Health Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
US9879065B2 (en) * 2012-09-14 2018-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing MHC class II-restricted MAGE-A3
EP3220928B1 (en) * 2014-11-20 2022-10-05 UMC Utrecht Holding B.V. A method of obtaining a preparation enrichmed in engineered t cells with exogenous immune receptors
PL3223850T3 (pl) 2014-11-26 2020-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptory limfocytów t przeciwko zmutowanemu kras
EP3901169A1 (en) 2015-09-15 2021-10-27 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
AU2017258745B2 (en) 2016-04-26 2022-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-KK-LC-1 T cell receptors
LT3494133T (lt) 2016-08-02 2022-12-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t ląstelės receptoriai

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008253267A (ja) * 1991-12-13 2008-10-23 Xoma Technology Ltd 改変抗体可変領域の調製のための物質ならびにその治療的用途
JPH11512284A (ja) * 1995-09-05 1999-10-26 ザ ジェネラル ホスピタル コーポレイション 単クローン性リンパ球及び利用方法
JP2003276960A (ja) * 2002-03-26 2003-10-02 Mitsubishi Electric Corp エレベーター制御システム
JP2016527230A (ja) * 2013-07-15 2016-09-08 アメリカ合衆国 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体
JP2017524372A (ja) * 2014-05-29 2017-08-31 アメリカ合衆国 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体
WO2016053339A1 (en) * 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
JP2017535253A (ja) * 2014-10-02 2017-11-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY, 2016, VOL.24, NO.6, PP.1078-1089, JPN6022035564, ISSN: 0004995494 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554674A (ja) * 2020-12-22 2023-12-28 ネオジン セラピューティクス ビー．ブイ． 遺伝子改変細胞追跡用ペプチドマーカー

Also Published As

Publication number Publication date
MA50748A (fr) 2020-08-12
SG11202003112QA (en) 2020-05-28
CN111417720A (zh) 2020-07-14
ES2960313T3 (es) 2024-03-04
EP4269595A2 (en) 2023-11-01
EP3692140B1 (en) 2023-07-19
AU2018345400A1 (en) 2020-05-07
IL273698B2 (en) 2025-07-01
JP7747724B2 (ja) 2025-10-01
US12227554B2 (en) 2025-02-18
JP2024050551A (ja) 2024-04-10
US20200254018A1 (en) 2020-08-13
KR102757789B1 (ko) 2025-01-20
AU2018345400B2 (en) 2024-06-20
IL273698B1 (en) 2025-03-01
WO2019070435A1 (en) 2019-04-11
KR20200064107A (ko) 2020-06-05
EP3692140A1 (en) 2020-08-12
IL273698A (en) 2020-05-31
EP4269595A3 (en) 2023-12-06
WO2019070435A8 (en) 2020-01-30
CA3077595A1 (en) 2019-04-11
CN111417720B (zh) 2025-02-07
FI3692140T3 (fi) 2023-10-11

Similar Documents

Publication Publication Date Title
JP7700159B2 (ja) Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法
JP7162530B2 (ja) 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
JP7048494B2 (ja) 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
JP2023038386A (ja) 細胞免疫療法のための方法および組成物
ES2891578T3 (es) Antígeno quimérico y receptores de células T y métodos de uso
JP7118887B2 (ja) 最適化されたレンチウイルス移入ベクターおよびその使用
CN112955465A (zh) 抗tcr抗体分子及其用途
JP7747724B2 (ja) マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
BR112020007710A2 (pt) métodos para produzir células que expressam receptor de antígeno quimérico
JP7064663B2 (ja) Ｉｌ－１３ｒａ２を標的とする抗体及びその応用
WO2022182890A1 (en) Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
JP2021536256A (ja) 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
CN112041432A (zh) Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
TW202144569A (zh) 用於調節免疫細胞中精胺酸含量之方法及組合物
US20240352087A1 (en) T Cell Receptors (TCR) to Human Papillomavirus Proteins, Compositions, and Uses Thereof
HK40031098B (en) Methods for selectively expanding cells expressing a tcr with a murine constant region
HK40031098A (en) Methods for selectively expanding cells expressing a tcr with a murine constant region
US20230019849A1 (en) Method for Preparing CD7-Negative, CD3-Positive T Cells
WO2025207642A1 (en) Cxcr3 isoforms to improve recombinant receptor trafficking
WO2025011662A1 (zh) 一种载体和体外转染非激活t细胞的方法

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210924

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240104

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240308